Company intelligence / Profile preview

Vyrix Pharmaceuticals

Greenwood Village, Colorado, United States

Ownership: Private
Development stage: Other

Overview

Vyrix’s lead candidate Zertane (tramadol, oral, for premature ejaculation) completed two European Phase 3 trials and additional Phase 1/2 studies; US registration trials were planned but not completed. Zertane-ED, a combination therapy targeting premature ejaculation and erectile dysfunction, was at preclinical/early clinical stage. No US or EU regulatory approvals were obtained, and Vyrix withdrew its IPO in 2014. Clinical development or commercialization as of 2025 is not active.[1][2][3][4][5][8][11][12]

Therapeutic areas: Men's Health
Modalities: Small molecule
Industry: Biotech

Partnerships

Paladin Labs (Canada, South Africa, LATAM, Sub-Saharan Africa, licensing/distribution agreement)Daewoong Pharmaceutical Co., Ltd. (Korea/Brazil, clinical and development partner)

Beyond the preview

Go deeper on Vyrix Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vyrix Pharmaceuticals.

Explore the full profile